Eema Fsh 75 Iu Injection

Product Description

EMA FSH 75IU INJECTION belongs to the class of drugs called hormones used in the treatment of female infertility in women whose ovaries do not produce eggs and in women receiving treatments like IVF (in-vitro fertilization). Infertility is unable to become pregnant after trying for a year. Female infertility may be caused due to different factors affecting ovulation (release of an egg from the ovary), fertilization (fusion of sperm and egg) and implantation (fertilized egg attaches to uterus lining).

EEMA FSH 75IU INJECTION contains Urofollitropin which works similarly to follicle-stimulating hormone (natural sex hormone). EEMA FSH 75IU INJECTION increases oestrogen production that stimulates the development of the egg and mature follicle in women having ovulation (release of an egg from the ovary) problems and those undergoing IVF treatments.

Effective Solution for Female Infertility

Eema Fsh 75 IU Injection offers targeted stimulation of ovarian follicles in women diagnosed with anovulation or ovarian dysfunction. By supporting the natural ovulation process, this therapy assists with increasing the likelihood of conception, especially in assisted reproductive technology (ART) cycles. This injection is strictly administered under medical supervision to ensure optimal outcomes and minimize potential risks.


Proper Reconstitution and Administration

This injection is supplied as a lyophilized powder and must be reconstituted with the provided sterile solvent before administration. Once reconstituted, the solution should appear clear to slightly opalescent. It is injected subcutaneously as directed by a healthcare provider. Proper preparation and administration are essential for maximizing therapeutic effectiveness and safety during treatment.


Essential Safety and Monitoring Guidelines

Use of Eema Fsh 75 IU Injection mandates careful monitoring, including regular ultrasound examinations to assess ovarian response. The medication is contraindicated in women with hypersensitivity to FSH, uncontrolled thyroid or adrenal dysfunction, current pregnancy, or certain ovarian cysts. Adverse effects such as headache, abdominal pain, and injection site reactions should be promptly reported to the physician.